Search Results
Your search for multiple myeloma matches 1442 pages
Showing 101 - 150Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Highlights From the 2023 ASH Annual Meeting & Exposition
Hordes of classical and malignant hematologists returned to the tranquil city of San Diego for the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition this past December. The packed agenda lit the Gaslight District up with neuron-searing data, creating an environment for...
Expert Point of View: Peter Voorhees, MD
Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Durham, North Carolina, introduced the plenary presentation of the phase III IsKia trial by Gay et al and further commented on the study for The ASCO...
Addition of Isatuximab to Carfilzomib-Based Regimen Doubles MRD Negativity Rates in Multiple Myeloma
In the phase III IsKia trial in newly diagnosed multiple myeloma, therapy incorporating the CD38-directed monoclonal antibody isatuximab-irfc with a carfilzomib-based regimen led to high rates of minimal residual disease (MRD) negativity at postconsolidation cutoffs, as reported at the 2023...
Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest
Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
STAb T-Cell–Based Immunotherapy in Multiple Myeloma
A novel immunotherapy based on STAb T cells may be more effective at treating multiple myeloma than chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Díez-Alonso et al in Science Translational Medicine. Background Multiple myeloma is the second most common...
Ephrin B2 Identified as Potential Therapeutic Target to Inhibit Multiple Myeloma Growth
Researchers have discovered that the ephrin B2 protein may drive the growth and development of multiple myeloma and uncovered that blocking part of the protein’s unique signaling pathway may inhibit progression of the disease, according to a recent study published by Sasine et al in Cancer...
DREAMM-7 Confirms Benefit of Triplet Regimen in Relapsed or Refractory Multiple Myeloma
Positive results were reported for belantamab mafodotin-blmf plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma, according to data from the phase III DREAMM-7 study presented at the ASCO Plenary Series: February 2024 Session (Abstract 439572). DREAMM-7...
Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy
Researchers may have uncovered a novel strategy to identify which patients may experience poorer outcomes from chimeric antigen receptor (CAR) T-cell therapy prior to treatment, according to a recent study published by Faramand et al in Blood Cancer Discovery. The findings indicate opportunities to ...
Unintentional Weight Loss May Be a Warning Sign of Cancer, Study Finds
Unintentional weight loss may be associated with an increased risk of receiving a cancer diagnosis within the next year, according to a recent study published by Wang et al in JAMA. Background Patients with advanced cancer often experience weight loss. However, weight loss is often not thought to...
Expert Point of View: Cynthia E. Dunbar, MD
In a press briefing at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, Cynthia E. Dunbar, MD, ASH Secretary and Chief of the Translational Stem Cell Biology Branch, Intramural Research Program of the National Heart, Lung, and Blood Institute, offered her thoughts on...
Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest
Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...
Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Real-World Experience Mirrors PERSEUS Findings
At the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers from Emory University presented a real-world comparison of the largest cohort of patients with newly diagnosed multiple myeloma consecutively treated with either bortezomib, lenalidomide, and dexamethasone ...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
The High Cost of Oral Agents for Relapsed and Refractory Multiple Myeloma
Late in 2023, Richardson et al shared the results of a phase I/II clinical trial (ClinicalTrials.gov identifier NCT03374085). They concluded that the “all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma.”1 Mezigdomide ...
Obesity and a Precursor of Multiple Myeloma
Patients with obesity may be more likely to have monoclonal gammopathy of undetermined significance, according to a recent study published by Lee et al in Blood Advances. Background Monoclonal gammopathy of undetermined significance—a benign hematologic condition characterized by an abnormal...
Novel Risk Model May Personalize Prognosis Prediction in Patients With Multiple Myeloma
Researchers have developed a novel computational model for personalized prognosis prediction in patients with newly diagnosed multiple myeloma, according to a new study published by Maura et al in the Journal of Clinical Oncology. Their model for individualized risk in multiple myeloma, or IRMMa,...
Minimizing the Severe Side Effects of Immunotherapy in Patients With Multiple Myeloma
Investigators have found that providing prophylactic treatment with the biological agent tocilizumab prior to immunotherapy may reduce the incidence of cytokine-release syndrome in patients with multiple myeloma, according to a study published by Kowalski et al in Blood Cancer Discovery. ...
I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy
Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival...
Pieter Sonneveld, MD, PhD, on Newly Diagnosed Multiple Myeloma: Phase III Findings on Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone
Pieter Sonneveld, MD, PhD, of the Netherland’s Erasmus MC Cancer Institute, discusses primary results from the Perseus trial, showing that for patients with newly diagnosed multiple myeloma who are eligible for transplantation, the combination of daratumumab plus bortezomib, lenalidomide, and...
Use of Elranatamab for Black Patients With Multiple Myeloma
Elranatamab may be safe and effective in Black patients with relapsed or refractory multiple myeloma, according to new findings presented by Varshavsky-Yanovsky et al at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 3333). Background Elranatamab—an...
Danai Dima, MD, on Multiple Myeloma: Update on Safety and Efficacy of Teclistamab
Danai Dima, MD, of the Taussig Cancer Institute, Cleveland Clinic, discusses teclistamab-cqyv, a B-cell maturation antigen approved in October 2022 for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Dr. Dima and her team evaluated the...
Daratumumab Plus VRd Outperforms VRd Alone for Multiple Myeloma
Newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone (VRd) had significantly higher rates of survival without disease progression compared with those who received VRd alone. Results from the phase ...
Patients With Multiple Myeloma May Experience Poorer Outcomes in the Real World Compared With Reported Outcomes From Clinical Trials
Researchers identified a 75% higher rate of mortality among patients treated for multiple myeloma in real-world hospital settings compared with rates reported in clinical trials involving common therapies. The new findings were presented by Visram et al at the 2023 American Society of Hematology...
Supportive Parents and Early Love of Science Lead to a Career in Hematology Oncology for Nina Shah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology, Oncology Research and Development at AstraZeneca. She is a hematologist who specializes in...
Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma
For the treatment of newly diagnosed multiple myeloma with high-risk features, a quadruplet regimen of the anti-CD38 antibody isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) induced high rates of measurable residual disease (MRD) negativity, both in transplant-eligible and...
Studies Explore Efficacy of Venetoclax in t(11;14)-Positive Myeloma
In the global randomized phase III CANOVA study, venetoclax plus dexamethasone (VenDex) demonstrated numerically longer progression-free survival compared with pomalidomide and dexamethasone (PomDex) in patients with t(11;14)-positive relapsed or refractory multiple myeloma, though the difference...
Having Colorectal Cancer at 32 Changed the Trajectory of My Life
I’ve been contending with health issues since I was 12, when I was diagnosed with Crohn’s disease. As I began my early 30s, I was feeling the healthiest of my life. I was working out 5 days a week and attributed sudden weight loss and fatigue to weight training and high-intensity Zumba classes....
Is Idecabtagene Vicleucel Effective in Patients With Multiple Myeloma, Regardless of Race?
The chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel may offer an overall survival benefit in patients with multiple myeloma, regardless of their race or ethnicity, according to a novel study published by Peres et al in Blood Advances. Background Multiple myeloma—a cancer of...
IVIG May Reduce Infection Risk Among Patients With Multiple Myeloma Receiving Anti-BCMA Therapy
Although the 5-year survival rate for multiple myeloma has increased over the past 2 decades—from about 35% in 2000 to approximately 62% in 2015—due to more effective therapies, the cancer remains incurable. According to the American Cancer Society, this year, nearly 36,000 individuals will be...
Accelerated Approval Granted for Use of Elranatamab-bcmm in Relapsed or Refractory Multiple Myeloma
On August 14, 2023, the bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager elranatamab-bcmm was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of...
Dendritic Cell Vaccine Plus Stem Cell Transplant for Multiple Myeloma
Although the development of new therapies for multiple myeloma has significantly improved response rates and outcomes for patients with the blood cancer, most patients eventually relapse, including those who initially achieved remission. A phase I study is investigating whether a dendritic cell...
Neighborhood Walkability and Risk of Obesity-Related Cancers
Residing in more walkable neighborhoods could protect against the risk of overall obesity-related cancers in female patients, according to a recent study published by India-Aldana et al in Environmental Health Perspectives. Background Obesity has previously been linked to an increased risk of...
Isa-KrD for Transplant-Eligible and -Ineligible High-Risk Newly Diagnosed Multiple Myeloma
In an interim analysis of a German phase II trial (MMG-CONCEPT) reported in the Journal of Clinical Oncology, Leypoldt et al found that Isa-KrD (isatuximab, carfilzomib, lenalidomide, and dexamethasone) produced high rates of measurable residual disease (MRD) negativity newly diagnosed patients...
Diabetes May Be Linked to Lower Survival Among Patients With Multiple Myeloma; Survival Outcomes May Be Race-Dependent
Patients with multiple myeloma who also have diabetes may experience worse overall survival outcomes compared with patients who don’t have diabetes, according to a recent study published by Shah et al in Blood Advances. The new findings demonstrated that the differences in survival may be dependent ...
Carfilzomib and Lenalidomide–Based Therapy in Primary Plasma Cell Leukemia
In a European phase II trial (EMN12/HOVON-129) reported in The Lancet Oncology, van de Donk et al found that the incorporation of carfilzomib and lenalidomide into induction, consolidation, and maintenance therapies was associated with good outcomes in both younger and older patients with primary...
Ajay K. Nooka, MBBS, Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Data for Elranatamab
Ajay K. Nooka, MBBS, of Winship Cancer Center of Emory University, discusses findings from a pooled analysis of MagnetisMM studies. The data showed that, in patients with relapsed or refractory multiple myeloma who have not yet been treated with B-cell maturation antigen–directed therapies,...
Accelerated Approval Granted for Talquetamab-tgvs in Treatment of Relapsed or Refractory Multiple Myeloma
On August 9, 2023, the bispecific GPRC5D (G protein–coupled receptor, class C, group 5)-directed CD3 T-cell engager talquetamab-tgvs was granted accelerated approval by the U.S. Food and Drug Administration for treatment of adults with relapsed or refractory multiple myeloma who have received at...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
Accelerating Progress Against Cancer and Other Life-Threatening Diseases
Cancer—and the quest to accelerate more effective treatments and potential cures for all life-threatening diseases—has perhaps shaped the life of financier Michael Milken more than his legendary career on Wall Street. In the early 1970s, Mr. Milken’s mother-in-law was diagnosed with metastatic...
The Immune System May Play Vital Role in Remission Duration Among Patients With Multiple Myeloma
Researchers have uncovered the vital role that the immune system may play in determining the duration of remission and progression-free survival in patients with multiple myeloma, according to a recent study published by Coffey et al in Nature Communications. The new findings suggested that the...
Relapsed or Refractory Multiple Myeloma: Mezigdomide Plus Dexamethasone
In a phase I/II trial (CC-92480-MM-001) reported in The New England Journal of Medicine, Paul G. Richardson, MD, and colleagues found that the combination of the novel cereblon E3 ubiquitin ligase modulator mezigdomide and dexamethasone showed activity in heavily pretreated patients with relapsed...
FDA Approves New Multiple Myeloma Combination Therapy
On September 11, the U.S. Food and Drug Administration (FDA) approved motixafortide (Aphexda) in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Motixafortide is...
More on Multiple Myeloma From ASCO 2023: Focus on Bispecific Antibodies
Two new bispecific antibodies—teclistamab and talquetamab—have been shown to be active in relapsed or refractory multiple myeloma when used in combination, including in patients with extramedullary disease, without compounding toxicity. Results of two clinical trials with these two agents were...
Selinexor Shows Activity as Maintenance Therapy for TP53 Wild-Type Endometrial Cancer in Phase III Trial
Long-term follow-up of selinexor maintenance therapy has demonstrated promising efficacy in patients with TP53 wild-type endometrial cancer, according to data presented during the ASCO Plenary Series: July 2023 Session.1 Selinexor is a selective inhibitor of nuclear export (SINE) approved for use...
Nikhil Munshi, MD, on Multiple Myeloma: Data From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Nikhil Munshi, MD, of Dana-Farber Cancer Institute, discusses the final safety and efficacy results from the phase Ib/II CARTITUDE-1 trial of ciltacabtagene autoleucel. This CAR T-cell therapy targets B-cell maturation antigen in patients with relapsed or refractory multiple myeloma. Longer median...
Accelerated Approval for Elranatamab-bcmm in Patients With Relapsed or Refractory Multiple Myeloma
On August 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elranatamab-bcmm (Elrexfio), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior...
